We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Ticker | Name | Price | Change | Change % | Volume | Trades |
---|---|---|---|---|---|---|
MTH | Mithril Resources Limited | 0.29 | 0.288 | 14,400.00% | 3,475,489 | 1,060 |
MGUO | Magnum Mining and Exploration Ltd | 0.006 | 0.003 | 100.00% | 450,000 | 2 |
CYPOA | Cynata Therapeutics Ltd | 0.045 | 0.018 | 66.67% | 7 | 1 |
AMSO | Atomos Limited | 0.008 | 0.003 | 60.00% | 2,115,620 | 7 |
ME1 | Melodiol Global Health Ltd | 0.003 | 0.001 | 50.00% | 1,538,332 | 28 |
AXP | AXP Energy Limited | 0.0015 | 0.0005 | 50.00% | 50,000 | 1 |
GCR | Golden Cross Resources Ltd | 0.003 | 0.001 | 50.00% | 1,313,016 | 4 |
NGSOA | Nutritional Growth Solutions Ltd | 0.003 | 0.001 | 50.00% | 2,500,000 | 2 |
AML | Aeon Metals Limited | 0.01 | 0.003 | 42.86% | 5,654,615 | 48 |
CHR | Charger Metals NL | 0.10 | 0.029 | 40.85% | 9,179,846 | 455 |
PIL | Peppermint Innovation Limited | 0.011 | 0.003 | 37.50% | 10,351,716 | 54 |
Data Will be Presented in Two Posters at the EASL Congress 2024 CAMBRIDGE, Mass., May 22, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transformation of cardiometabolic diseases, today announced that pre-clinical data suggests that DA-1241, a novel G-Protein-Coupled Receptor 119 (GPR119) agonist, in combination with semaglutide (Wegovy®), improves liver fibrosis and demonstrates additive hepatoprotective effects in pre-clinical metabolic dysfunction-associated steatohepatitis (MASH) models compared to either treatment alone. Members of the Dong-A ST Research Center and Contract Research Organization, Gubra, will present the data in two poster presentations at the EASL Congress 2024, ...
LISHUI, China, May 21, 2024 /PRNewswire/ -- Tantech Holdings Ltd (NASDAQ: TANH) ("Tantech" or the "Company") announced today that it received a notice of non-compliance from Nasdaq Stock Market LLC ("Nasdaq") on May 20, 2024 stating that, as a result of not having timely filed its annual report on Form 20-F for the year ended December 31, 2023, the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1), which requires timely filing of periodic financial reports with the Securities and Exchange Commission. This notice has no immediate effect on the listing or trading of the Company's common shares on ...
WiSA Technologies, Inc. (the “Company”) (Nasdaq: WISA), a developer of spatial, wireless sound technology for smart devices and next-generation home entertainment systems, reported first quarter 2024 financial results in its Form 10-Q, which was filed on May 20, 2024. In its conference call and presentation today at 8:00 am PT / 11:00 am ET, management will discuss its WiSA E initiatives, the Company’s results, and provide a general business update.
VICTORIA, BC, May 22, 2024 /PRNewswire/ - Eupraxia Pharmaceuticals Inc. ("Eupraxia" or the "Company") (TSX: EPRX) (NASDAQ: EPRX), a clinical-stage biotechnology company leveraging its proprietary DiffuSphere™ technology to optimize drug delivery for applications with significant unmet need, today announced that it will host a virtual key opinion leader ("KOL") event on Wednesday, May 29, 2024, at 10:00 AM ET.
Ticker | Name | Price | Change | Change % | Market Cap | Volume |
---|---|---|---|---|---|---|
BTC | Bitcoin | 70,015.29 | -115.97 | -0.17% | 1.37T | 5,198,086,326 |
ETH | Ethereum | 3,708.03 | -81.38 | -2.15% | 446.63B | 6,710,330,975 |
BNB | Binance Coin | 618.63 | 0.213137 | 0.03% | 97.85B | 466,281,941 |
USDT | Tether USD | 0.99981 | 0.00002 | 0.00% | 97.82B | 343,151,529 |
SOL | Solana | 179.28 | 1.14 | 0.64% | 79.05B | 1,459,932,110 |
STETH | stETH | 3,709.26 | -78.25 | -2.07% | 36.42B | 30,535,524 |
XRP | Ripple | 0.5326 | -0.0045 | -0.84% | 29.12B | 405,072,789 |
USDC | USD Coin | 1.00 | 0.00 | 0.00% | 28.07B | 1,449,651,469 |
DOGE | Dogecoin | 0.16583 | -0.0045 | -2.64% | 23.81B | 819,570,707 |
TONCOIN | Wrapped TON Coin | 6.30 | -0.029901 | -0.47% | 21.87B | 88,348,425 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions